Mirae Asset Global Etfs Holdings Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 16,270 shares of PHAT stock, worth $312,872. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,270Holding current value
$312,872% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$194 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$144 Million27.45% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$67.2 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$60.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$56.3 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $753M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...